HighCape Partners

Wellinks specializes in wearable health technologies designed to enhance clinical outcomes. Founded in 2014, the company is renowned for its innovative smart strap that monitors scoliosis brace wear duration and tightness, empowering patients, parents, and doctors with real-time data for informed treatment decisions.

Cybrexa Therapeutics is a biotechnology company focused on developing an innovative class of small molecule DNA repair inhibitors aimed at improving cancer treatment. Founded in 2016 and based in New Haven, Connecticut, Cybrexa utilizes a proprietary peptide-based technology that specifically targets the tumor microenvironment. This approach allows for enhanced drug delivery and increased therapeutic efficacy, particularly when combined with existing chemotherapies and radiotherapies. By enabling the safe administration of higher drug doses, Cybrexa's therapeutics aim to expand the efficacy of current anticancer agents and address significant unmet medical needs in oncology. The company's novel platform has the potential to redefine drug delivery paradigms and enhance patient outcomes in cancer care.

Wellinks specializes in wearable health technologies designed to enhance clinical outcomes. Founded in 2014, the company is renowned for its innovative smart strap that monitors scoliosis brace wear duration and tightness, empowering patients, parents, and doctors with real-time data for informed treatment decisions.

Cybrexa Therapeutics is a biotechnology company focused on developing an innovative class of small molecule DNA repair inhibitors aimed at improving cancer treatment. Founded in 2016 and based in New Haven, Connecticut, Cybrexa utilizes a proprietary peptide-based technology that specifically targets the tumor microenvironment. This approach allows for enhanced drug delivery and increased therapeutic efficacy, particularly when combined with existing chemotherapies and radiotherapies. By enabling the safe administration of higher drug doses, Cybrexa's therapeutics aim to expand the efficacy of current anticancer agents and address significant unmet medical needs in oncology. The company's novel platform has the potential to redefine drug delivery paradigms and enhance patient outcomes in cancer care.

Cybrexa Therapeutics is a biotechnology company focused on developing an innovative class of small molecule DNA repair inhibitors aimed at improving cancer treatment. Founded in 2016 and based in New Haven, Connecticut, Cybrexa utilizes a proprietary peptide-based technology that specifically targets the tumor microenvironment. This approach allows for enhanced drug delivery and increased therapeutic efficacy, particularly when combined with existing chemotherapies and radiotherapies. By enabling the safe administration of higher drug doses, Cybrexa's therapeutics aim to expand the efficacy of current anticancer agents and address significant unmet medical needs in oncology. The company's novel platform has the potential to redefine drug delivery paradigms and enhance patient outcomes in cancer care.